A-dmDT390-bisFv not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)”In the company’s words, NCT02943642 on ClinicalTrials.gov
- Tested for
- Mycosis Fungoides
- Main trialPhase 2
- “This study evaluates the effectiveness - as judged by complete response - of a single four-day treatment with the fusion protein A-dmDT390-bisFv(UCHT1) compared to oral Zolinza (Vorinostat), in a randomized 2-arm trial after a maximum of 12 months of treatment. Patient eligibility is stage IB/IIB mycosis fungoides with mSWAT \< 50 who have never had lymphoid disease or a prior bone marrow / HSCT transplant.”In the company’s words, NCT02943642 on ClinicalTrials.gov
Other drugs for Mycosis Fungoides
- PTX-100Prescient Therapeutics, Ltd. · Phase 2
- MDSY-1240Medsyn Biopharma, LLC · Phase 1/2
- VG712Virogen Biotechnology Inc. · Phase 2
- GolcadomideCelgene · Phase 1/2
- FenretinideSciTech Development, Inc. · Phase 1
- DuvelisibSecuraBio · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Withdrawn | 13 May 2026 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026